Compelling evidence indicates that the endothelium-derived potent vasoconstrictor endothelin-1 (ET-1) stimulates aldosterone secretion by interacting with specific receptors. Although two different ET-1 receptors have been identified and cloned, the receptor subtype involved in mediating aldosterone secretion is still unknown. Accordingly, we wished to investigate whether the genes of ET-1 and of its receptors A and B are expressed in the normal human adrenal cortex. We designed specific primers for ET-1 and the ETA and ETB receptors genes and developed a reverse transcription polymerase chain reaction (RT-PCR) with chemiluminescent quantitation of the cDNA. In addition, we carried out 'I ET-1 displacement studies with cold ET-1, ET-3 and the specific ETA and ETB ligands BQ123 and sarafotoxin 6C. Localization of each receptor subtype was also investigated by autoradiography. Binding experiments were first individually analyzed by Scatchard and Hofstee plot and then coanalyzed by the nonlinear iterative curve fitting program Ligand. Histologically normal adrenal cortex tissue, obtained from kidney cancer patients (n = 7), and an aldosterone-producing adenoma (APA), which is histogenetically derived from the zona glomerulosa (ZG) cells, were studied. Results showed that the ET-1, ETA and ETB mRNA can be detected by RT-PCR in all adrenal cortices as well as in the APA. The best fitting of the 125I ET-1 displacement binding data was consistently provided by a two-site model both in the normal adrenal cortex (F = 22.1, P < 0.0001) and in the APA (F = 18.4, P < 0.0001). In the former the density (B..n) of the ETA and ETB subtype was 2.6±0.5 pmol/mg protein (m±SEM) and 1.19±0.6, respectively. The dissociation constant (Kd) of ET-1, S6C, 
Introduction
The secretion of aldosterone is regulated by several factors. The three major secretagogues are angiotensin H, ACTH, and potassium, whereas dopamine, sodium, and the atriopeptins exert an inhibitory effect ( 1) . Recently, the very potent 21 -amino acid vasoconstrictor peptide endothelin-1 (ET-1),' has also been shown to stimulate aldosterone secretion both in vitro and in vivo (2) (3) (4) (5) (6) (7) , and to enhance ACTH-and. angiotensin Hstimulated aldosterone secretion from cultured bovine adrenal cells (8, 9) . Furthermore, it has been reported that the chronic infusion of ET-1 raises plasma aldosterone concentration in rats and that isolated zona glomerulosa (ZG) cells from the infused animals showed an enhancement of their basal production of aldosterone, which was consistent with de novo synthesis of the aldosterone-synthesizing enzymes (10, 11) . Accordingly, it has been hypothesized that ET-1 plays a role in the regulation of aldosterone in several conditions, including liver cirrhosis ( 12) , congestive heart failure ( 13, 14) , preeclampsia ( 15 ) , liver transplantation ( 16, 17) , endotoxiemic shock ( 18) , primary and malignant hypertension (19, 20) , which are characterized by enhanced aldosterone secretion and endothelial damage. Indeed, the latter can turn-on synthesis and secretion of ET-1, and thereby enhance aldosterone secretion through endocrine-paracrine mechanisms. Since the chronic infusion of ET-1, a well known mitogen (10) , was found to cause a notable hypertrophy of ZG cells it is also conceivable that ET-1 may be involved in enhancing aldosterone secretion in primary aldosteronism, a rare cause of secondary hypertension where no known stimulus of aldosterone secretion has been identified so far (1) .
Two different ET-1 specific receptors, the ETA and ETB, which have been identified, pharmacologically characterized, and cloned (21) , appear to mediate the physiological effects of ET-1. Autoradiographic evidence of ET-1 specific binding to the adrenal cortex and medulla has been reported in several species (22) (23) (24) (25) (26) . ET-1 specific binding to the ZG has been consistently identified in rat, porcine and human adrenals (23, 26, 27) , as well as to cultured calf adrenal ZG cells (2) . Although the data suggested the presence of two ET-1 receptors (26) , no selective endothelin antagonist was available at that time and therefore no conclusive information on whether ET-1 receptor subtypes exist in the adrenal cortex could be gained. In vitro experiments with ET-1, ET-2, ET-3, and the weak ETB agonist sarafotoxin B have thereafter suggested, although not conclusively proven, the presence of a high and a low affinity binding site in cultured calf glomerulosa cells (26) . Furthermore, mRNA for both the ETA and the ETB receptor has been detected by Northern blot analysis by Imai et al. (27) in three human adrenal glands obtained from patients with an aldosterone producing adenoma. However, ET-1 saturation isotherms were consistent with the existence of only one population of ET-1 receptors, suggesting that only one receptor subtype mRNA was effectively translated into protein. Thus, the question on whether endothelin receptor subtypes with possible different functional role exist in the normal human adrenal cortex is still unanswered.
The recent development of the selective antagonist for the ETA receptor BQ123 and of the weak ETB receptor agonist sarafotoxin 6C (S6C) has provided new tools for investigating the distribution and pharmacological properties of endothelin receptors. Furthermore, molecular medicine techniques such as the reverse transcription polymerase chain reaction (RT-PCR) allowed investigating genes expression in different organs starting from very limited amount of tissue, such as that available in the clinical setting.
Thus, the purpose of this study was to investigate whether ETA and ETB receptors are expressed in the normal human adrenal cortex and to assess their anatomical distribution as well as their binding properties. To further establish whether the ETA and ETB receptors are present in the ZG, an adrenal tumor, the aldosterone-producing adenoma (APA), which is histogenetically derived from ZG cells, was also studied.
Methods
Preparation of adrenal tissues. Adrenal cortices were obtained from consenting patients undergoing unilateral nephrectomy for kidney cancer (n = 7). All adrenals were histologically normal. To rule out the possibility of contamination from the medulla, that is rich in ET-1 binding sites, the utmost care was taken to dissect out only the outer portion of the adrenal cortex. In addition, we studied an APA obtained at surgery from a patient with ET-3 and BQ123. Note that curves for (S 6 C) and BQ123 are biphasic, suggesting two binding sites.
phoresis followed by Southern vacuum blotting (LKB, Pharmacia) onto a nylon membrane. To further evaluate the kinetic of the amplification reaction slot blot analysis was carried out with a commercially available apparatus (Milliblot, Millipore, Milano, Italy). The PCR products transferred on a nylon membrane (Zeta-Probe GT; Biorad Laboratories, Milano, Italy) were UV cross-linked (Stratagene UV-Crosslinker 1800; Stratagene-Duotech Milano, Italy). Detection of the digoxigenin-labeled amplification products on the nylon membrane was carried out by a high affinity antidigoxigenin-antibody Fab-fragments conjugated to alkaline phosphatase using a chemiluminescent detection kit (DIG; Boehringer Mannheim, Germany). Light generated via dephosphorilation of the chemiluniscent substrate was used to impress XAR x-ray (Eastman Kodak Co., Rochester, NY) films with a 20-min exposure, as in an autoradiographic procedure. Quantification of the PCR products was carried out by measuring the integrated optical density of the autoradiographies with an image analyzer IBAS 2000 (Zeiss, Unterkochen, Germany). Plots of the log integrated optycal density vs number of cycles were then elaborated; the cycle number (N50) that corresponded to the half-maximal PCR products was also calculated, as an estimate of the relative amounts of initial amplifiable template of the f3-actin, ETA, and ETB genes (40) .
Autoradiography. Two normal adrenal cortices (including the capsule) and one APA immediately frozen in isopentane cooled in liquid nitrogen in the operating room were studied. Frozen 10-15-'sm sections were cut in a cryostat (Leitz 1720 Digital; Leitz, Wetzlar, Germany) at -20°C, and processed according to Kuhar (41) and Palacios et al. (42) . Sections were preincubated in Tris-HCl 50 mM, pH 7.4, containing 0.01% bacitracine, 135 mM NaCl, 10 Fig. 1 . Cold ET-1 was the most potent in displacing 125I ET-l followed by S6C, ET-3, and BQ123. As it can be seen, both S6C and BQ123 produced biphasic competition binding curves, suggesting the presence of two binding sites. Analysis of the saturation and displacement experiments showed Hill and pseudo-Hill coefficient values less than unity for all ligands, suggesting the presence of multiple binding sites (Table I ). Further analysis with the nonlinear curve-fitting program LIGAND revealed that the best fitting was provided by a two-site model, as shown by the significant values of the Fratio (Table I ) (32) . Simultaneous analysis of the results of the 125I ET-1 binding displacement with ET-1, S6C and BQ123 using the LIGAND subroutine again showed that a two-site model provided the best fitting of the experimental data (Fratio 22.07, P < 0.0001). (Fig. 2 B, see below) and the autoradiographic findings (see Fig. 6 , and below). Estimated B.,X were lower (1.33 and 0.8 pmol/mg protein), whereas the Kd were identical to those of Table I. PCR results. The RT-PCR consistently allowed detection of the ET-1, ETA, and ETB mRNA in all adrenal specimen examined. An example of an EtBr stained 1.5% agarose gel is shown in Fig. 2 of the expected size for both the ETA and ETB receptors and for the control f3-actin gene were easily detected, both in the normal adrenals (Fig. 3 A) and in the APA tissue (Fig. 3 B) . In the latter, a notable difference is evident in the expression of the ETA and ETB receptor between both normal and adenomatous adrenal cortex tissue and the renal cortex, despite no evident difference in the expression of the /3-actin gene. No amplification was seen in the control PCR containing either no cDNA (water) or total RNA with no prior reverse transcription, thereby ruling out the possibility of false positive results and of amplification of genomic DNA, respectively (Fig. 3) .
An x-ray film of a slot-blot containing the amplification products of different PCR cycles from two of the five normal adrenal cortices is shown in Fig. 4 . The kinetics of amplification of the ETA, the ETB and the f3-actin cDNA is reported in Fig.   5 , where the log of integrated OD of amplified DNA is plotted vs number of PCR cycles. The ETA curve is shifted to the right as compared with the others; the slopes of the ETA and ETB amplification are similar, thereby suggesting a similar efficiency of amplification (40) . The N50, i.e., the number of cycles at which half-maximal amplification was attained, resulted to be significantly lower (P < 0.05) for ETB (22 ing on both their muscular and endothelial components (Fig. 6  A) . The addition of an excess of cold ET-1 virtually displaced all 125I ET-1 binding (Fig. 6 B) . BQ-123 markedly attenuated labeling in ZG and completely eliminated it in the vascular tunica muscularis, without apparently affecting 125I ET-1 of the capillary endothelium in ZF (Fig. 6 C) . Sarafotoxin 6C determined a moderate attenuation of ZG and completely eliminated it in ZF; however, vascular smooth muscle cells were still labeled (Fig. 6 D) . Similar results, but a less intense binding to parenchymal cells, were obtained on the APA tissue (Fig. 7) .
Discussion
Endothelins are a family of recently discovered peptides with multiple biological actions, including very potent and long-lasting vasoconstriction, mitogenesis, and stimulation of endothelium-derived relaxing factors (EDRFs), ANP, renin, argininvasopressin, and aldosterone release (45, 46) . In anesthetized dogs the infusion of endothelin, aside from widespread hemodynamic effects, consistently induced a two-four-fold long-lasting increase of aldosterone secretion, as well as an increase of plasma renin activity (4). However, the stimulation of aldosterone secretion appeared to be independent of the renin-angiotensin system, since it was observed also in vitro in dispersed ZG cells (2, 3, 1 1 ), and even after pretreatment with the angiotensin converting enzyme inhibitor captopril (46). Further studies have indeed shown that ET-1 directly stimulates aldosterone secretion, although less potently than angiotensin II, via a Ca2+-dependent mechanism (7, 47) . This stimulation is deemed to involve enhancement of the synthesis of prostaglandins, since in perfused slices of frog adrenal gland it was associated with a release of prostaglandins and was abolished by indomethacin (7) . In addition, ET-1 potentiates the aldosterone response to angiotensin II and ACTH (8, 9) , possibly via an interaction with different receptor subtypes (26) . Of interest, ACTH has been found to increase the release of endothelin-1 from the adrenals thereby suggesting that ET-1 is a mediator of ACTHstimulated aldosterone secretion (48 the presence of specific, saturable endothelin binding sites with an average Kd of 0.086 nM (2) . However, this was not a proof of the existence of only a single class of ET-1 receptors, given the selectivity ratio of ET-1 for the two identified receptors ETA and ETB and their similar relative densities. Therefore, no conclusion could be made based on ET-1 saturation binding isotherms alone (32, 33) . Further studies on the same experimental model with the endothelin analogue sarafotoxin 6 B, which was equipotent to ET-1 in stimulating aldosterone secretion, and with ET-3, a very poor stimulator of aldosterone secretion, have thereafter suggested the presence of two different endothelin receptors; a high-affinity (Kd of 0.05 nM) and a low-affinity (Kd of 0.17 nM) receptor (26) . Our study takes advantage of two facts: the recent identification and cloning of two human endothelin receptors (38, 39, 49) and the development of specific antagonists for each one of them (29, 50) . The isopeptide-selective ETA receptor, identified from a human cDNA library (21, 38) preferentially binds ET-1 and is specifically antagonised by BQ123. Its mRNA has been detected in the central nervous system as well as in the aorta, heart and lung (21) . At variance, the nonisopeptide-selective ETB was found to bind ET-1, ET-2, and ET-3 with the same affinity and to be antagonised by S6C (29, 51 (Table I) (Fig. 7) . Of interest, in five patients with primary aldosteronism Zeng et al. (56) reported that endothelin stimulated the secretion of aldosterone in vitro from the cortex surrounding aldosterone-producing adenomas in a dose-dependent fashion, but not from the tumors. Although further studies are needed before drawing more definitive conclusions, our experiments provide evidence that the mRNAs for both the ETA and ETB receptor subtypes are detectable and that these receptors can be functionally measured in the APA tissue.
In addition, lower B., values of both receptor subtypes and a less intense '25I ET-1 binding at autoradiography (Fig. 7) were observed in the APA tissue. Accordingly, these findings-may suggest that the absence of aldosterone response in vitro to ET-1 is not due to lack of expression of the genes encoding for the two ET-1 receptor subtypes, but may rather be ascribed to a decreased rate of transcription resulting in a lower density of the density of both receptors in the tumor tissue as compared to the normal adrenal cortex.
